ENTITY
WuXi XDC Cayman

WuXi XDC Cayman (2268 HK)

84
Analysis
Health CareChina
WuXi XDC Cayman Inc. operates as a leading contract testing, development and manufacturing organization focused on the global antibody drug conjugates and broader bioconjugate market. The Company provides bioconjugation discovery, analytical development, intermediate and conjugation manufacturing, and other services. WuXi XDC Cayman provides its services worldwide.
more
bullishWuXi XDC Cayman
01 Apr 2025 19:11

Wuxi XDC Placement - Following Biologics Playbook, past Deals Have Been Mixed

WuXi AppTec (2359 HK) aims to raise around US$250m via selling around 3.5% stake in WuXi XDC Cayman (2268 HK). In this note, we talk about the deal...

Logo
316 Views
Share
bullishWuXi XDC Cayman
10 Jan 2025 19:26

Wuxi XDC Placement - A Repeat of Biologics Placement Saga, Last Deal Did Well

WuXi AppTec (2359 HK) aims to raise around US$150m via selling around 3% stake in WuXi XDC Cayman (2268 HK). It has sold earlier in Nov 24 as well.

Logo
621 Views
Share
bearishWuXi XDC Cayman
01 Nov 2024 05:52

WuXi XDC Cayman:  The Stock Still Trades at a Premium Multiple, Lack of Upside Catalysts

WuXi XDC Cayman stock rebounded strongly and trades above IPO offer price of HK$20.60. In my insight, I discuss the company’s valuation and...

Logo
304 Views
Share
bearishWuXi XDC Cayman
28 Aug 2024 08:55

WuXi XDC Cayman (2268.HK) 24H1- High Growth of ADC Market Ensures Investment Logic, but Risks Remain

​Global ADC market growth ensures short-term performance stability,but WuXi XDC faces challenges due to factors beyond its control.Geopolitical...

Logo
371 Views
Share
bearishWuXi XDC Cayman
08 May 2024 07:00

Wuxi XDC Lock-Up - US$300m Lockup Expiry Could See Some Selling Owing to the Regulatory Overhang

WuXi XDC Cayman (2268 HK) was listed in Hong Kong on 17th Nov 2023 after raising US$470m. Its six-month lockup will expire on 16th May 2024.

Logo
554 Views
Share
x